Sunday December 8, 2019

New Drug to Give Hopes to Bone Marrow Cancer Patients

It reduced the risk of progression or death by more than 50 per cent in both groups

0
//
Cancer
Cancer Ribbon. Pixabay

A therapeutic drug has been found to improve outcomes and survival rates for patients with a serious type of bone marrow cancer.

In a clinical trial by researchers at Newcastle University in Britain, patients with newly diagnosed myeloma were treated with a drug called lenalidomide.

The results, published in the journal The Lancet Oncology, showed an improvement for those who received lenalidomide drug, compared to those not receiving it.

“This is a major breakthrough as it shows that the long-term use of lenalidomide significantly improves the time myeloma patients stay in remission after initial therapy,” said Professor Graham Jackson from the Northern Institute for Cancer Research at Newcastle.

Myeloma is a cancer of the plasma cells and it can affect several areas of the body, such as the spine, skull, pelvis and ribs. Current treatment usually involves chemotherapy and a stem-cell transplant.

cancer
New drug offers hope for bone marrow cancer patients. Pixabay

“It is a huge step and, importantly, identifies that for younger patients lenalidomide improves their overall survival for this difficult-to-treat bone marrow cancer,” Jackson said.

“Our research highlights that lenalidomide should be considered for newly diagnosed patients following stem-cell transplantation,” he added.

As part of the study, a total of 1,137 newly diagnosed patients were randomly assigned to lenalidomide maintenance therapy and 834 patients to observation – this was after they completed their initial treatment.

Also Read- Narendra Modi Accuses Congress of Aiding Those Who Want to Weaken Army

The results show that lenalidomide can prolong the average remission time by more than two years in younger patients and by well over a year in older, less fit patients.

It reduced the risk of progression or death by more than 50 per cent in both groups. (IANS)

Next Story

Genetic Variations Influence Risk of Developing Cancer: Study

Study found that variations in the regions that regulate the expression of oncogenes and tumour suppressor genes affect cancer risk

0
Cancer
While minor genetic changes only have a small impact on Cancer risk, the variations analysed in this study are numerous and common in the population. Pixabay

Shedding new light on why some people develop cancer while others do not, a new study has found that a person’s risk of developing cancer is affected by Genetic variations in regions of DNA that do not code for proteins, previously dismissed as “junk DNA”.

This study, published in the British Journal of Cancer, shows that inherited cancer risk is not only affected by mutations in key cancer genes, but that variations in the DNA that controls the expression of these genes can also drive the disease.

The researchers believe that understanding how non-coding DNA affects the development of this disease could one day improve genetic screening for cancer risk.

And in the future, this could lead to new prevention strategies, or help doctors diagnose the disease earlier, when it is more likely to be treated successfully.

“What we found surprised us as it had never been reported before — our results show that small genetic variations work collectively to subtly shift the activity of genes that drive cancer,” said lead researcher of the study John Quackenbush, Professor at Harvard T.H. Chan School of Public Health in the US.

Genetic
Shedding new light on why some people develop Cancer while others do not, a new study has found that a person’s risk of developing cancer is affected by genetic variations in regions of DNA that do not code for proteins, previously dismissed as “junk DNA”. Pixabay

“We hope that this approach could one day save lives by helping to identify people at risk of cancer, as well as other complex diseases,” Quackenbush said.

The researchers investigated 846 genetic changes within non-coding stretches of DNA, identified by previous studies as affecting cancer risk.

These Single Nucleotide Polymorphisms (SNPs) are particular positions in the human genome where a single letter of the genetic code varies between people.

Unlike mutations in coding DNA, such as BRCA, that are rare but significantly raise a person’s risk of developing cancer, non-coding SNPs are relatively common in the population but only slightly increase cancer risk.

The team analysed whether there was a correlation between the presence of a particular SNP and the expression of particular genes.

In total, they looked at over six million genetic variants across 13 different body tissues.

Genetic
The researchers believe that understanding how non-coding DNA affects the development of this disease could one day improve genetic screening for cancer risk. Pixabay

They found that variations in the regions that regulate the expression of oncogenes and tumour suppressor genes affect cancer risk.

The study also revealed that these cancer-risk SNPs tend to be specifically located in regions that regulate the immune system and tissue-specific processes — highlighting the importance of these cellular processes to the development of cancer.

ALSO READ: Rise in Phone-related Injuries Linked to iPhone, Pokemon Go

“While minor genetic changes only have a small impact on cancer risk, the variations analysed in this study are numerous and common in the population,” said Emily Farthing, senior research information manager at British charity Cancer Research UK. (IANS)